Darifi: Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers

Sponsor

University of Cape Town (Other)

Overall Status

Terminated

CT.gov ID

NCT03892161

Collaborator

Wits Reproductive Health and HIV Institute (Other), Desmond Tutu HIV Centre (Other)

Enrollment

Location

Arms

7.4

Actual Duration (Months)

2.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The DaRifi study aims:

Develop adjusted doses of darunavir/ritonavir for use in HIV-infected patients requiring co-treatment of TB with a rifampicin-based regimen.
Compare the steady state pharmacokinetics of doubled doses of DRV/r with rifampicin (in once daily and 12-hourly approaches) to standard daily doses without rifampicin.
Twenty-eight volunteers will be enrolled for a target of 24 participants completing the study.

Condition or Disease	Intervention/Treatment	Phase
HIV Infections	Drug: Darunavir/ritonavir 800/100 mg tablet Drug: Rifampicin 600mg QD tablet and DTG 50mg BD	Phase 1

Detailed Description

A significant barrier to the use of better tolerated antiretrovirals in many low-to-middle income countries (LMIC), where tuberculosis (TB) is endemic, is a lack of evidence to support their use in patients with TB. Access to optimal protease inhibitor (PI)-based regimens for patients with and without TB is urgent. Switching rifampicin to rifabutin, a weak inducer that does not significantly reduce PI concentrations, is recommended in high income countries for patients on boosted PIs who develop TB. However, rifabutin is not available in most LMIC where TB is typically treated with fixed dose combination tablets.

We will enrol virologically suppressed participants on a second-line DRV/r regimen without TB. Based on data from a Physiologically-Based PK model, we selected two adjusted doses of DRV/r (1600/200 mg daily and 800/100 mg 12 hourly) with RIF for comparison to plasma exposures with DRV/r 800/100 mg daily without RIF, in a cross-over design.

Baseline DRV steady state PK will be determined and RIF added for 7 days, then the dose of ritonavir will be increased to 200 mg; 7 days later the dose of DRV will be increased; after another 7 days participants will be crossed over to the alternative adjusted DRV dose.

DRV will be measured in plasma samples after observed doses at baseline and after each dose adjustment. Non-compartmental analysis will be used to estimate the PK measures. Clinical adverse events, ALT, and bilirubin will be monitored every 2 to 3 days during treatment with RIF.

Study Design

Study Type:

Interventional

Actual Enrollment :

17 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Intervention Model Description:

A phase I, open-label, cross-over, single center, PK drug-drug interaction study will be conducted in 24 medically stable HIV-1 infected adults with viral suppression (viral load <50 copies/mL).A phase I, open-label, cross-over, single center, PK drug-drug interaction study will be conducted in 24 medically stable HIV-1 infected adults with viral suppression (viral load <50 copies/mL).

Masking:

Triple (Participant, Care Provider, Investigator)

Masking Description:

Eligible volunteers will be switched from their standard of care PI to DRV/r 800/100 mg daily, and intensive sampling for measurement of drug concentrations will be performed at steady state. Rifampicin (600-750 mg daily depending on body weight) will then be started and subsequently the protease inhibitor doses escalated to DRV/r 1600/200 mg daily (participants randomized to arm A), OR 800/100 mg 12-hourly (arm B) for 7 days, after which patients will be switched from the daily to the 12-hourly dosing schedule (arm A) or vice versa (arm B) for a further 7 days. Rifampicin will then be stopped but the increased doses of DRV/r will be continued for a further week, before participants are switched back to their standard-of-care ART regimen. Dolutegravir (DTG) 50 mg twice daily (the dose which overcomes any interaction with rifampicin (Dooley 2013) will be added to minimize the risk of viral rebound due to possible suboptimal protease inhibitor exposures during the study.

Primary Purpose:

Treatment

Official Title:

Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers

Actual Study Start Date :

Apr 12, 2018

Actual Primary Completion Date :

Nov 22, 2018

Actual Study Completion Date :

Nov 22, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Standard dose DRV/r Standard dose DRV/r 800/100mg without Rifampicin	Drug: Darunavir/ritonavir 800/100 mg tablet Standard dose DRV/r administered
Experimental: Standard DRV/r with Rifampicin Rifampicin 600mg QD will be added and darunavir/ritonavir steady state pharmacokinetic analysis will be performed.	Drug: Darunavir/ritonavir 800/100 mg tablet Standard dose DRV/r administered Drug: Rifampicin 600mg QD tablet and DTG 50mg BD Rifampicin and DTG added
Experimental: Boosed ritonavir 200mg Rifampicin 600mg QD continued with ritonavir 200mg dose doubled QD and darunavir remains 800mg QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.	Drug: Darunavir/ritonavir 800/100 mg tablet Standard dose DRV/r administered Drug: Rifampicin 600mg QD tablet and DTG 50mg BD Rifampicin and DTG added
Experimental: Double dose DRV/r 1600/200mg QD Rifampicin 600mg QD and DTG QD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.	Drug: Darunavir/ritonavir 800/100 mg tablet Standard dose DRV/r administered Drug: Rifampicin 600mg QD tablet and DTG 50mg BD Rifampicin and DTG added
Experimental: Double dose DRV/r 800/100mg BD Rifampicin 600mg QD and DTG BD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.	Drug: Darunavir/ritonavir 800/100 mg tablet Standard dose DRV/r administered Drug: Rifampicin 600mg QD tablet and DTG 50mg BD Rifampicin and DTG added

Outcome Measures

Primary Outcome Measures

Darunavir plasma concentrations nanogram per milliliter (ng/ml) [1 year]
Darunavir plasma concentrations will be compared with rifampicin and without rifampicin.

Secondary Outcome Measures

Alanine Transaminase (ALT) blood level (iu/L) [1 Year]
Clinical safety will be monitored, ALT liver enzyme tests will be evaluated every 3 days.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria

Male or female
Aged 18 to 60 years, inclusive
Weighing > 38 kg
BMI > 18.5 kg/m2
HIV-1 infected
HIV-1 RNA <50 copies/mL
CD4+ lymphocyte count > 200 cells/L
C-reactive protein <10 mg/L
Established on current ART regimen of boosted protease inhibitor plus 2 NRTIs for at least 3 months.
Women must be postmenopausal, surgically sterile or practicing an effective birth control method (established before and maintained throughout the trial). Women who are not sexually active must agree to use an effective birth control method if they become heterosexually active during the trial.
Understand the purpose of and procedures required for the study and having confirmed they are willing to participate in the study by signing the informed consent document.

Exclusion criteria (volunteers meeting any of the criteria will be excluded)

TB (confirmed or suspected)
Any symptoms of TB - as assessed by the WHO symptom-screening algorithm: self-reported or documented weight loss, cough, night sweats or fever.
Clinical or laboratory evidence of significantly impaired hepatic function, or documented hepatic cirrhosis
Clinical or laboratory evidence of acute viral hepatitis
Co-infected with HBV or HCV.
ALT grade 2 or higher (as defined by DAIDS grading table (ALT >2.5 x ULN)
DAIDS grade 3 or 4 laboratory abnormality
Active (not clinically stabilized >4 weeks) AIDS defining illness (Category C conditions according to the Center for Disease Control Classification System for HIV infection) with the following exceptions:
Stable cutaneous Kaposi's Sarcoma (no internal organ involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the study.
Estimated creatinine clearance <50 mL/min.
Active clinically significant renal or gastro-intestinal disease.
Any active clinically significant or life-threatening disease, medical or psychiatric condition, or findings during screening, that in the investigator's opinion would compromise the safety of the participant or the study outcome, or their ability to comply with the study procedures.
Chronic medical requirement for any drugs that are known to affect the PK of the study drugs.
Active drug/alcohol abuser.
Pregnant or breastfeeding.
Increased risks of drug side effects/hypersensitivity reactions e.g. haemophilia or history of sulfonamide allergy.
Currently enrolled in an investigational drug study or has participated in an investigational drug study within the 4 weeks before screening.
Unable to comply with peri-study restrictions

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Clinical Research Centre	Cape Town	Western Cape	South Africa	7725

Sponsors and Collaborators

University of Cape Town
Wits Reproductive Health and HIV Institute
Desmond Tutu HIV Centre

Investigators

Principal Investigator: Helen McIlleron, PhD, University of Cape Town

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:

Helen Margaret McIlleron, Professor, University of Cape Town

ClinicalTrials.gov Identifier:

NCT03892161

Other Study ID Numbers:

Darifi

First Posted:

Mar 27, 2019

Last Update Posted:

Apr 3, 2019

Last Verified:

Apr 1, 2019

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 3, 2019